ProSomnus Sleep Technologies received FDA Class II clearance for its RPMO2 OSA Device, the first theragnostic device combining oral appliance therapy with multi-night physiologic monitoring for obstructive sleep apnea (OSA). This device offers continuous, accurate oxygen saturation and pulse rate monitoring via an embedded oximeter in a dental appliance, enabling personalized, data-driven treatment. The FDA clearance supports its safety and effectiveness, marking a shift toward connected, patient-centered sleep apnea care. ProSomnus aims to improve treatment adherence and outcomes by integrating real-time monitoring with precision oral therapy, positioning the device as a key innovation in managing OSA as a chronic disease.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
